Immu conference next week - Vnda

[chinaman711]

IMMU conference next week VNDA wow

[chinaman711]

IMMU news----Immunomedics to get patent for B-cell disorder treatment

PrintDisable live quotesRSSDigg itDel.icio.usBy Gabriel Madway
Last Update: 11:37 AM ET Dec 7, 2006



SAN FRANCISCO (MarketWatch) -- Immunomedics Inc. (IMMU : IMMU
News , chart, profile, more
Last:


Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
, , ) said Thursday it will be awarded a U.S. patent covering methods for treating B-cell disorders using the company's monoclonal antibody. The patent will be issued Dec. 19. The Morris Plains, N.J.-based biopharmaceutical said the allowed claims cover the use of its product, hA20, for the treatment of B-cell lymphomas, leukemias and autoimmune diseases. Immunomedics shares rose 48 cents, or 17%, to $3.24 in Thursday morning trade.

[ub3rn00ber]

Wow thats a huge gain for Vnda...

You think IMMU's confrence will go good?

[chinaman711]

I loaded up at 3.17 and 3.19, if i remember right immu went to 60 plus back in the 90's and i was in at 6 plus : ).

[chinaman711]

IMMU up on 5 times the volume so someone must think the conference will go well. The group has been hot too. Good luck

[chinaman711]

Thursday's Health Winners & Losers

By Althea Chang
TheStreet.com Staff Reporter
12/7/2006 2:19 PM EST
Click here for more stories by Althea Chang




Shares of biopharmaceutical company Tercica (TRCA - commentary - Cramer's Take - Rating) jumped Thursday after the company said it won a lawsuit against Insmed (INSM - commentary - Cramer's Take - Rating) for infringing a patent the company licensed from Genentech (DNA - commentary - Cramer's Take - Rating).
The jury verdict, coming from a U.S. District Court in Northern California, orders Insmed to pay $7.5 million and 15% royalties for damages pertaining to its drug Iplex for past sales of up to $100 million, and 20% in royalties for sales greater than $100 million. Tercica's shares were up 4.2% to $6.15, while Insmed's shares plummeted 18.3% to $1.07.

Immunomedics (IMMU - commentary - Cramer's Take - Rating) gained 11.7% to $3.14 after the company said it was granted a patent on methods for treating blood disorders using certain disease-fighting monoclonal antibody technologies. The patent covers treatments for B-cell disorders, which affect the body's immune responses.

Shares of drug developer Vanda Pharmaceuticals (VNDA - commentary - Cramer's Take) jumped 70% to $26.35 Thursday after the company said treatment with its antipsychotic drug iloperidone significantly improved measures of schizophrenia symptoms when compared with a placebo. Results were even greater in a subgroup of patients with certain genetic traits, according to clinical trial results.

Cancer drugmaker Celgene (CELG - commentary - Cramer's Take - Rating) named David Gryska chief financial officer. The company also appointed Dr. Thomas Daniel president of global research. Shares were down 2.6% to $56.09.

Alfacell (ACEL - commentary - Cramer's Take) announced plans to hire a president and chief operating officer, a newly created position at the company. The move comes in anticipation of the company's new drug application filing with the Food and Drug Administration for its flagship product, Onconase. The company's board of directors has formed a search committee to recruit its COO. Shares were up 8.4% to $1.55.


Page 1 2 NEXT PAGE >

[chinaman711]

More news out today-- LookupFinance Search



Press Release Source: Immunomedics, Inc.


Low Doses of Humanized Anti-Cd20 Antibody Reported Active in Non-Hodgkin's Lymphoma
Monday December 11, 8:00 am ET
- Follow-up Clinical Data Presented at the 48th Annual Meeting of American Society of Hematology -


ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, presented on Sunday, December 10th, follow-up clinical data that showed the Company's humanized anti-CD20 (hA20) monoclonal antibody was active in patients with non-Hodgkin's lymphoma (NHL) at a dose as low as 120 mg/m(2). Results of this open-label, multi-center Phase I/II study were reported at the 48th Annual Meeting of American Society of Hematology (ASH) in Orlando, FL, by Franck Morschhauser, MD, Centre Hospitalier Regional Universitaire de Lille, Lille, France, the study's lead investigator.
ADVERTISEMENT




In the United States, NHL is the most common form of blood cancer, affecting over 360,000 people. Each year, there are approximately 50,000 new cases and almost 25,000 deaths from this disease in the United States.

According to Dr. Morschhauser, "These results with hA20 compare favorably to a published report of a similar patient population retreated with rituximab after at least one prior course of this antibody, where overall and complete response rates of 40% and 11%, respectively, were observed for the usual dose of 375 mg/m(2) weekly for four weeks (TA Davis et al., J Clin Oncol 2000; 18:3135-43). Throughout the doses studied with hA20, an encouragingly high complete response rate, averaging 22%, and durable responses at each dose level were observed in these low-grade or follicular lymphoma patients."

Cynthia Sullivan, President and CEO of Immunomedics, commenting on the low-dose responses seen with hA20, said, "The difference between the two antibodies is that rituximab has been approved at a dose of 375 mg/m(2). With hA20, we can go down to 120 mg/m(2) and achieve similar response rates and B-cell depletion. The advantages of a lower dose include faster infusion rates and fewer side effects." She further commented, "Because hA20 is a humanized antibody, thus far we have not seen any immune reaction to it." Ms. Sullivan also pointed out that during the study, no serious infusion related events were reported.

A total of 57 adult patients with recurrent NHL were enrolled and were infused once weekly for four consecutive weeks with 120, 200, 375, or 750 mg/m(2) of hA20. Fifty patients had received at least one prior rituximab- containing regimen. Treatment responses from 48 assessable patients (32 with follicular lymphoma and 16 with non-follicular lymphoma) with at least one post-treatment evaluation were reported at the meeting. The overall objective response rate (partial and complete responses) was 44% (21/48), with 17% (8/48) of patients having a complete response (CR/CRu).

In the 32 patients with follicular lymphoma, the overall response rate was 47% (15/32), with a complete response rate of 22% (7/32). Responders were across all dose groups, even at the lowest dose of 120 mg/m(2) (approximately one-third the conventional dose of rituximab) where 36% (5/14) were responders and 21% (3/14) had a complete response. In non-follicular lymphomas, the overall responses rate was 38% (6/16), including one complete response in marginal zone lymphoma. Higher overall response rates with up to 50% complete responses were observed at higher doses. In a median follow-up of 11 months post therapy, 9/21(43%) had continuing responses, including 4 with long-lived responses (15-20 months).

"We expect to complete this study soon and to advance the development of this humanized CD20 antibody in NHL as well as autoimmune diseases," Ms. Sullivan said. "While we continue to discuss out-licensing this product with potential partners, we are simultaneously developing a subcutaneous formulation. hA20's efficacy at low doses given the relatively small amount of protein involved, affords us the opportunity to develop a subcutaneous formulation, potentially providing the benefits of ease of use and patient acceptance."

[ub3rn00ber]

At least it isnt dead in the water. With this news, why the decline?

[chinaman711]

IMMU has had a nice run up in the last few weeks and not much of a pullback. Needs to close over 3.25 and then it could run imo.

[Thierry Martin]

544

[ub3rn00ber]

so anyone sell yet, im sitting on a 11% profit, and wondering what to do.

[ub3rn00ber]

just broke 52 wk high in afterhours, up 17%. Think its going to fall friday or skyrocket?

[ub3rn00ber]

4.01 booya +.50 above 52wk high

[ub3rn00ber]

out for a ez 30%

[chinaman711]

IMMU looks to test 4 soon and if we get thru 4 could see 6 imo. Good luck

[chinaman711]

IMMU volume picking up and some buying going on. 55,000 shares traded in the 1st 40 minutes and then 100k traded in the next 10 minutes might be 1 to watch if it gets thru 4. Good luck